Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097058 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAGAAMAPTALDH1A1 | |
| SCHEMBL11757368 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAMAPTALDH1A1NOX1 | |
| SCHEMBL11512166 | 0.83 | KMT2A (0.71) | SMN1; SMN2LMNAGAAALDH1A1ALOX12 | |
| SCHEMBL11533572 | 0.83 | SMN1; SMN2 (0.76) | SMN1; SMN2LMNAMAPTALDH1A1NOX1 | |
| SCHEMBL11504808 | 0.81 | NOX1 (0.77) | SMN1; SMN2LMNAMAPTALDH1A1NOX1 | |
| SCHEMBL8725948 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAGAAMAPTALDH1A1 | |
| SCHEMBL11419541 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2GAAMAPTALDH1A1NOX1 | |
| SCHEMBL11512780 | 0.81 | LMNA (0.57) | SMN1; SMN2LMNAGAAMAPTALDH1A1 | |
| SCHEMBL10488934 | 0.80 | MAPT (0.76) | SMN1; SMN2LMNAGAAMAPTALDH1A1 | |
| SCHEMBL14434226 | 0.80 | POLB (0.73) | SMN1; SMN2LMNAMAPTALDH1A1NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135492-B2 | Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | WYETH | 2003-06-26 | — | — | US | disclosed |
| US-4148799-A | Process for the preparation of 2-aryliminothiazoline solutions | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119889-A1 | 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis | FFAR4, FFAR1, MSR1 | SMN1; SMN2 4084/4885LMNA 1945/4885GAA 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.